Regulatory ProgressManagement intends to meet with the FDA to discuss a potential regulatory pathway for ADG126, and a favorable regulatory update could be a catalyst for the stock.

Therapeutic PotentialAdagene presented positive data from its ongoing Phase 1/2 study with ADG126 at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, which further solidified ADG126’s therapeutical potential in MSS-CRC.

Bears Say

Market OpportunityAnalyst is moving to the sidelines based on a combination of factors including the relatively small market opportunity, regulatory uncertainty, and safety concerns with targeting CTLA-4.

Regulatory CompetitionRegulatory uncertainty is a concern as another company is testing a similar immunotherapy combination for a similar treatment.

Safety ConcernsThree patients have discontinued treatment in the 10 mg/kg Q3W cohort, indicating potential issues with the treatment regimen.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

0.02% Mutual Funds

11.50% Other Institutional Investors

88.48% Public Companies and

Individual Investors

Detailed Ownership Overview >

ADAG FAQ

What was Adagene, Inc.’s price range in the past 12 months?

Adagene, Inc. lowest stock price was $1.32 and its highest was $3.58 in the past 12 months.

What is Adagene, Inc.’s market cap?

Adagene, Inc.’s market cap is $93.75M.

When is Adagene, Inc.’s upcoming earnings report date?

Adagene, Inc.’s upcoming earnings report date is Aug 27, 2025 which is in 33 days.

How were Adagene, Inc.’s earnings last quarter?

Adagene, Inc. released its earnings results on Mar 24, 2025. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.33 by $0.04.

Is Adagene, Inc. overvalued?

According to Wall Street analysts Adagene, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Adagene, Inc. pay dividends?

Adagene, Inc. does not currently pay dividends.

What is Adagene, Inc.’s EPS estimate?

Adagene, Inc.’s EPS estimate is -0.34.

How many shares outstanding does Adagene, Inc. have?

Adagene, Inc. has 47,109,554 shares outstanding.

What happened to Adagene, Inc.’s price movement after its last earnings report?

Adagene, Inc. reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.33. Following the earnings report the stock price went up 5.357%.

Which hedge fund is a major shareholder of Adagene, Inc.?

Currently, no hedge funds are holding shares in ADAG

Adagene Stock Smart Score

Underperform

Fundamentals

Return on Equity

-55.14%

Trailing 12-Months

Asset Growth

-22.84%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Adagene, Inc.

Adagene (ADAG) is a biotechnology company that operates in the pharmaceutical and life sciences sectors. The company specializes in the development of innovative antibody-based therapies, utilizing its proprietary Dynamic Precision Library (DPL) technology to create novel therapeutics targeting various diseases, including cancer. Adagene's core focus is on advancing its pipeline of products through clinical trials and strategic collaborations to bring effective treatments to market.